据介绍，为满足中国及全球医疗市场对高品质医用材料日益增长的需求，路博润在上海松江生产基地完 成了战略布局，进一步扩大了医用级TPU产品的本土化制造品类。此次产能扩充不仅为现有本地医用级 产品矩阵注入新动能，也显著提升了对亚太客户需求的响应速度与供应链的可靠性和灵活性。 同时，新建的路博润技术卓越中心深度融合了路博润全球的材料科学实力与本地化应用开发能力，成为 高性能膜品应用领域的重要创新平台。中心将面向多个行业，具备从TPU配方设计与开发、加工工艺到 终端性能测试的全流程能力。针对医疗领域，技术卓越中心不仅专注于牙科膜材的创新应用，更积极拓 展多元前沿医用膜品领域，助力客户加速产品研发，提升本土创新效率，拓宽医疗材料的应用边界。 中化新网讯 9月25日，路博润宣布两项关键举措，以加强其对中国医疗行业的长期承诺。路博润正积极 扩大其医用级热塑性聚氨酯(TPU)的本地生产能力，并正式成立"路博润高性能膜品技术卓越中心"。 亚太区副总裁刘茂树表示："本地化产能的提升和技术卓越中心的建立，是路博润深耕本地市场、强化 区域产业协同的重要里程碑。" ...

Core Insights - The article highlights the operational efficiency and economic growth of the Alashankou Comprehensive Bonded Zone, showcasing its transformation from a transit node to an integrated open hub over 11 years [3][4]. Group 1: Economic Performance - In 2024, the bonded zone's total foreign trade import and export volume reached 38.284 billion yuan, marking a year-on-year increase of 28.8%, with imports alone surging by 52.3% to 26.916 billion yuan [3][4]. - The bonded zone has seen a rise in its ranking to 75th among 154 bonded zones in China based on development performance evaluations [3]. Group 2: Infrastructure Development - The bonded zone has established over 700,000 square meters of standardized factory buildings and 200,000 square meters of open storage yards, along with a grain silo capable of storing 1 million tons [5]. - A comprehensive upgrade of the railway dedicated line and the construction of various specialized lines for different types of cross-border goods have been completed, enhancing logistical efficiency [5]. Group 3: Industry Growth - The bonded zone hosts 331 enterprises, fostering a diverse industrial cluster that includes modern commerce logistics, agricultural processing, metal mineral processing, medical materials, and equipment manufacturing [3][5]. - Significant projects such as a 160 million yuan railway dedicated line upgrade and a 560 million yuan cross-border e-commerce industrial park are operational, contributing to economic growth [5]. Group 4: Innovation and New Business Models - The newly established 82,000 square meter cross-border e-commerce industrial park has attracted 13 enterprises, achieving an import and export volume of 3.427 billion yuan in 2024 [7]. - The bonded zone is developing high-energy platforms for bulk commodity trading, cross-border e-commerce, and border trade, aiming to enhance its role as a modern comprehensive bonded zone connecting domestic and Eurasian markets [7].

Core Viewpoint - The article highlights the recent financing round completed by Jiangsu Baisafe Biotechnology Co., Ltd. (Baisafe), aimed at accelerating technological innovation and global market expansion in the field of biomedical materials surface modification technology [1][3]. Company Overview - Baisafe was established in February 2017 and is headquartered in Jiangsu Province, focusing on the field of biomedical materials surface modification technology. The company has assembled a high-end talent team with international vision and expertise in interdisciplinary fields such as biomedical materials, chemical engineering, and mechanical automation [3]. - The company has created a comprehensive technical service platform for functional coating, covering a range of self-developed medical coating products, automated coating equipment/production lines, and AI quality inspection and analysis instruments [3]. Key Products and Technologies - Hydrophilic Lubricating Coating: Offers excellent lubrication performance, significantly reducing friction resistance during the use of medical devices, enhancing operational smoothness and safety [4]. - Anticoagulant Coating: Effectively prevents blood coagulation on the surface of medical devices, reducing the risk of thrombosis and extending the lifespan of medical devices [4]. - Antibacterial Coating: Possesses strong antibacterial properties, effectively inhibiting bacterial growth and reproduction, thereby reducing infection risks and ensuring patient health [4]. - Anticrystallization Coating: Prevents crystal deposition on the surface of medical devices, maintaining their performance and functionality [4]. - Drug-Releasing Coating: Enables precise drug release, improving therapeutic effects while reducing drug dosage and side effects [4]. Financing History - 2017: Initial angel round financing upon establishment [4]. - 2019: Completed Series A financing [4]. - 2021: Completed Series B financing [4]. - April 2022: Completed over 100 million yuan Series B financing led by Huatai Zijing, with participation from existing shareholders [4]. - August 2022: Completed several million yuan Series B+ financing led by Yuansheng Venture Capital [4]. - 2025: Completed a new financing round led by Jinyumaowu, with support from existing shareholders [1][4].